AIM ImmunoTech expects ~$4.2M gross from warrant inducement at $0.48/share; new warrants at $0.60

AIM ImmunoTech Inc.

Existing warrants from May 2024, Sep 2024, Jul 2025 exercised at reduced exercise price of $0.48; gross proceeds ~$4.2M if fully exercised.
New Class H inducement warrants at 200% coverage; exercise price $0.60, 5-year term, subject to stockholder approval.
Placement agent: Ladenburg Thalmann; 8% cash fee, 6% warrant coverage, plus 0.75% management fee.
Proceeds to be used for working capital and general corporate purposes.
Company to call stockholder meeting within 75 days post-closing to approve issuance of Inducement Warrant Shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Inducement Letter with holders of Existing May 2024 Warrants, Existing September 2024 Warrants, and Existing July 2025 Warrants valued at approximately $4.20 million (effective 2026-05-07).

Action: entry
Agreement: equity purchase
Counterparty: holders of Existing May 2024 Warrants, Existing September 2024 Warrants, and Existing July 2025 Warrants
Value: approximately $4.20 million
Effective: 2026-05-07

Exact text from the filing

On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. entered into Engagement Agreement with Ladenburg Thalmann & Co. Inc. (effective 2026-05-07).

Action: entry
Agreement: underwriting
Counterparty: Ladenburg Thalmann & Co. Inc.
Effective: 2026-05-07

Exact text from the filing

The Company entered into an engagement agreement (the “Engagement Agreement”) with Ladenburg Thalmann & Co. Inc. (the “Placement Agent”) to act as its placement agent in connection with the transactions summarized above.

View on SEC.gov

Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-021863

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.